ACTO Achieves Gold Partner Status with Veeva After Nearly a Decade of Collaboration

ACTO Achieves Veeva Gold Product Partner Status

In a significant milestone for the health and pharmaceutical sectors, ACTO has reached the prestigious status of Gold Product Partner with Veeva, recognizing nearly a decade of successful collaboration aimed at enhancing customer outcomes. This achievement reflects ACTO's commitment to excellence in its services and its innovative integration of artificial intelligence with human intelligence, tailored specifically for the life sciences domain.

Founded in 2017, ACTO has progressively advanced its partnership with Veeva, moving from a Silver Product Partner status in 2021 to its recent elevation to Gold Partner. This journey underscores ACTO's dedication to optimizing field team performance, regulatory compliance, and effective customer interactions across pharmaceutical and biotechnology sectors.

"In an industry that is constantly evolving, it is essential for field teams to stay ahead with the latest approved content, and at the same time engage healthcare professionals with confidence," stated Parth Khanna, CEO of ACTO. This commitment to keeping pace with innovations has led to ACTO developing validated integrations with several Veeva applications, including Veeva PromoMats, Veeva MedComms, and Veeva Vault CRM.

Through these innovative platforms, ACTO enables its clients to streamline their workflows, connecting training, field execution, and AI capabilities with trustworthy data and content. The integration not only empowers sales representatives and medical science liaisons (MSLs) to continually optimize their performance, but also allows them to access real-time operational insights which are crucial in delivering up-to-date information during client engagements.

One of the standout offerings from ACTO is its AI-driven role-play simulation tool, CxZone. This platform allows sales representatives to practice essential conversations using approved promotional messages and content directly from Veeva's PromoMats while MSLs engage in scientific exchanges using medically approved content from Veeva MedComms. Such capabilities are critical in today’s fast-paced medical landscape where every interaction could influence outcomes.

Moreover, ACTO Talk TRx™ enhances user experience by providing access to current approved content stored in Veeva systems while integrating key conversation points and best practice tips for healthcare interactions.

Kristn Peck, Vice President of Alliances at Veeva, expressed her confidence in ACTO, stating, "Becoming a Gold Product Partner illustrates ACTO's continuous investment in delivering integrated and validated solutions that truly support the life sciences industry."

Looking forward, both companies are set to showcase their collaborative innovations at Fierce PharmaWeek in Philadelphia from September 14-17. Interested attendees are encouraged to meet with ACTO representatives to learn more about the integration of AI in training and customer engagement processes.

For more information, visit ACTO’s official website at www.acto.com or follow on LinkedIn for the latest updates and news. ACTO is currently trusted by 14 of the top 50 pharmaceutical firms and leading biotech organizations, channeling the essence of collaboration and technology to revolutionize how therapies reach patients post-regulatory approval. By leveraging AI capabilities, ACTO is not only enhancing operational efficiencies but is also freeing up team members to focus on strategic execution and meaningful human connections—elements that are vital in patient-centric care.